Evidence map›Paper›PMID 40507815›Full record

ReviewInternational journal of molecular sciences2025

Biological Actions of Bile Acids via Cell Surface Receptors.

Yoshimitsu Kiriyama, Hiroshi Tokumaru, Hisayo Sadamoto, Hiromi Nochi

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. An Adaptive Cholic Acid Dimer for Selective Encapsulation.International journal of molecular sciences · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yoshimitsu KiriyamaKagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Takamatsu 760-8542, Japan.ORCID 0000-0002-7653-483X
Hiroshi TokumaruKagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Takamatsu 760-8542, Japan.
Hisayo SadamotoKagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Takamatsu 760-8542, Japan.ORCID 0000-0003-1838-0649
Hiromi NochiKagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Takamatsu 760-8542, Japan.ORCID 0000-0003-2352-8716

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bile acids (BAs) are synthesized in the liver from cholesterol and are subsequently conjugated with glycine and taurine. In the intestine, bile acids undergo various modifications, such as deconjugation, dehydrogenation, oxidation, and epimerization by the gut microbiota. These bile acids are absorbed in the intestine and transported to the liver as well as the systemic circulation. BAs can activate many types of receptors, including nuclear receptors and cell surface receptors. By activating these receptors, BAs can exert various effects on the metabolic, immune, and nervous systems. Recently, the detailed structure of TGR5, the major plasma membrane receptor for BAs, was elucidated, revealing a putative second BA binding site along with the orthosteric binding site. Furthermore, BAs act as ligands for bitter taste receptors and the Leukemia inhibitory factor receptor. In addition, the Mas-related, G-protein-coupled receptor X4 interacts with receptor activity-modifying proteins. Thus, a variety of cell surface receptors are associated with BAs, and BAs are thought to have very complex activities. This review focuses on recent advances regarding cell surface receptors for bile acids and the biological actions they mediate.

Indexed as

Bile Acids and SaltsReceptors, Cell SurfaceAnimalsHumansReceptors, G-Protein-CoupledBile Acids and SaltsReceptors, Cell SurfaceReceptors, G-Protein-Coupledbile acidbitter taste receptorGPBARgut microbiomegut microbiotaLIFRMRGPRX4muscarinic receptorS1P2RTAS2RTGR5

Identifiers

PMID40507815
PMCPMC12154436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.